Breaking News Instant updates and real-time market news.

NTIP

Network-1 Technologies

$3.00

(0.00%)

, SYNA

Synaptics

$48.81

-0.35 (-0.71%)

18:50
06/19/18
06/19
18:50
06/19/18
18:50

On The Fly: After Hours Movers

HIGHER: Network-1 Technologies (NTIP) up 11.7% after securing new patents... Synaptics (SYNA) up 11.2% after confirming merger talks with Dialog Semiconductor... Walgreens Boots Alliance (WBA) after inclusion in Dow Jones Industrial Index... Prothena (PRTA) up 1.8% after Parkinson's trial data. DOWN AFTER EARNINGS: La-Z-Boy (LZB) down 7.1%... Oracle (ORCL) down 3.6%... FedEx (FDX) down 0.5%. ALSO LOWER: Anika Therapeutics (ANIK) down 19.8% after CINGAL 16-02 data... Kindred Biosciences (KIN) down 3.0% after equity offering... Starbucks (SBUX) down 1.9% after lowering Q3 comps view... General Electric (GE) down 1.5% after being removed from Dow Jones Industrials index... Vale (VALE) down 0.5% after equity offering.

NTIP

Network-1 Technologies

$3.00

(0.00%)

SYNA

Synaptics

$48.81

-0.35 (-0.71%)

WBA

Walgreens Boots Alliance

$64.61

0.47 (0.73%)

PRTA

Prothena

$14.99

0.43 (2.95%)

LZB

La-Z-Boy

$33.25

0.1 (0.30%)

ORCL

Oracle

$46.29

-0.25 (-0.54%)

FDX

FedEx

$258.35

-5.295 (-2.01%)

ANIK

Anika Therapeutics

$45.99

0.9 (2.00%)

KIN

Kindred Biosciences

$10.00

-0.55 (-5.21%)

SBUX

Starbucks

$57.43

0.22 (0.38%)

GE

General Electric

$12.96

-0.24 (-1.82%)

VALE

Vale

$12.97

-0.21 (-1.59%)

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 22

    Jun

  • 28

    Jun

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

  • 20

    Sep

  • 21

    Sep

  • 20

    Jun

NTIP Network-1 Technologies
$3.00

(0.00%)

SYNA Synaptics
$48.81

-0.35 (-0.71%)

06/11/18
CHLM
06/11/18
NO CHANGE
CHLM
Buy
Synaptics may consider offer closer to $80 per share, says Craig-Hallum
Craig-Hallum analyst Tony Stoss notes that Synaptics (SYNA) reportedly rejected a $59 per share all cash bid from Dialog Semiconductor (DLGNF). The analyst does not believe Synaptics would accept a $59 per share offer given where the stock has traded in the past and recalls the company reportedly turned down a $110 per share offer from a Chinese bidder in 2016. Stoss thinks Synaptics would likely consider an offer closer to $80 per share. He reiterates a Buy rating on Synaptics shares.
06/11/18
JPMS
06/11/18
NO CHANGE
Target $52
JPMS
Overweight
Synaptics offer price could be $66-$75 per share, says JPMorgan
If Synaptics (SYNA) is exploring a sale to Dialog Semiconductor (DLGNF) at higher than $59 per share or $2B as reported Friday by Bloomberg, then there should be room for the talks to continue given Dialog's net cash position, JPMorgan analyst Paul Coster tells investors in a research note. The analyst sees a path forward even without synergies given the deal's strategic rationale. He cautions, however, that Synaptics was reported to have turned down a higher bid by a Chinese Consortium in 2016 and that Tsinghua's 9% stake in Dialog could be a "CFIUS red-flag." Coster has an Overweight rating on Synaptics with a $52 price target. The analyst sees a potential offer price for the company in the $66-$75 per share range. Combined EBITDA of $495M, synergies as high as $100M, and solid balance sheets provide room for an all-cash bump, Coster writes.
06/12/18
KEYB
06/12/18
NO CHANGE
KEYB
Apple iPhone inventories normalize, Galaxy S9 continue to disappoint, says KeyBanc
KeyBanc analyst John Vinh says his latest carrier surveys indicate stable sell-through of Apple's (AAPL) iPhone 8/X, and in line with store expectations. Accordingly, days of inventory have normalized at about 5 DOI and are consistent with healthy levels seen in past cycles, he adds. Conversely, the analyst notes that sell-through of the Samsung's (SSNLF) GS9 continues to deteriorate, accompanied by an increase in DOI. However, he notes a significant reduction in absolute inventories. While GS9 gives him pause, stable sell-through, and normalized iPhone 8/X inventories leave him incrementally more constructive ahead of the 2H ramp of the new iPhone 9 cycle. Vihn recommends investors continue to own Broadcom (AVGO), Skyworks (SWKS), and Synaptics (SYNA).
05/18/18
JPMS
05/18/18
NO CHANGE
Target $52
JPMS
Overweight
Synaptics added to Analyst Focus List at JPMorgan
JPMorgan analyst Paul Coster added Synaptics to his firm's Analyst Focus List as a short-term trade idea. He expects the stock to trade higher into year-end due to the second-half of the year ramp in new products that he thinks will buoy growth and margins. Coster has an Overweight rating on Synaptics with a $52 price target.
WBA Walgreens Boots Alliance
$64.61

0.47 (0.73%)

04/24/18
LEER
04/24/18
NO CHANGE
LEER
Amazon shelving pharma supply efforts to hospitals not surprising, says Leerink
Leerink analyst David Larsen notes that Amazon (AMZN) is said to be shelving its pharmaceutical supply efforts to hospitals, which he does not see as a suprise given several barriers to entry. The consumer market has always been Amazon's core competency, though he expects it will be a long, gradual, and difficult process of building up an online drug portfolio with an initial focus likely on generics. The analyst believes the risk of Amazon entering retail in the near term is reduced significantly. Nonetheless, Larsen thinks risk remains longer term for retail pharmacies such as CVS (CVS) and Walgreens Boots Alliance (WBA).
05/29/18
MZHO
05/29/18
NO CHANGE
Target $77
MZHO
Buy
Walgreens Boots Alliance price target lowered to $77 from $87 at Mizuho
Mizuho analyst Ann Hynes views Walgreens Boots Alliance's sell-side event last week as "strange." Management highlighted the company was focused on a new strategy for the stores, but would not share any details on the strategy for competitive reasons, Hynes tells investors in a research note. The analyst, however, keeps a Buy rating on the shares citing Walgreens' current valuation, "strong" cash flow and likely limited downside risk to adjusted earnings estimates.
05/23/18
LEER
05/23/18
NO CHANGE
Target $70
LEER
Market Perform
Walgreens Boots Alliance price target lowered to $70 from $75 at Leerink
Leerink analyst David Larsen lowered his price target for Walgreens Boots Alliance to $70 from $75 as healthcare hub strategy is taking time and headwinds continue. The analyst reiterates a Market Perform rating on the shares.
04/17/18
MZHO
04/17/18
NO CHANGE
MZHO
Amazon news removes 'unprecedented overhang' on drug sellers, says Mizuho
After CNBC reported yesterday afternoon that Amazon (AMZN) has decided to shelve its plan to sell and distribute pharmaceutical products, Mizuho analyst Ann Hynes said she had thought Amazon's current logistics and distribution model would not translate into healthcare. However, based on conversations with investors, she believes the magnitude of the overhang that Amazon presented for drug distributors and retail pharmacies was "unprecedented." While drug pricing is still a concern, she notes that the CNBC report removes one overhang on the drug supply chain stocks. Hynes remain a buyer of CVS Health (CVS) and Walgreens (WBA) and keeps Neutral ratings on Rite Aid (RAD) as well as on drug distributors AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK).
PRTA Prothena
$14.99

0.43 (2.95%)

04/24/18
04/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alcoa (AA) downgraded to Neutral from Buy at Citi with analyst Alexander Hacking saying the stock is up 60% year-over-year. 2. Dynagas LNG (DLNG) downgraded to Underperform from Market Perform at Wells Fargo with analyst Michael Webber saying another distribution cut is possible given expensive dropdowns from the company's private sponsor. 3. Skyworks (SWKS) downgraded to Neutral from Buy at Mizuho with analyst Vijay Rakesh saying the effects of a maturing handset cycle could start to impact the RF suppliers. 4. Prothena (PRTA) downgraded to Neutral from Buy at BTIG and to Perform from Outperform at Oppenheimer. 5. Donegal Group (DGICA) downgraded to Neutral from Outperform at Boenning & Scattergood. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/18
BTIG
04/24/18
DOWNGRADE
BTIG
Neutral
Prothena downgraded to Neutral from Buy at BTIG
BTIG analyst Robert Hazlett downgraded Prothena to Neutral from Buy after the PRONTO study read out negatively, which led directly to the discontinuation of the entire NEOD001 program. Despite noting that the company has programs "that appear quite promising," Hazlett prefers to move to the sidelines with important catalysts now farther out, with a readout for its 002 program in Parkinson's due in 2020.
05/21/18
LEHM
05/21/18
DOWNGRADE
Target $12
LEHM
Underweight
Prothena downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham downgraded Prothena to Underweight and cut his price target for the shares to $12 from $14. The analyst sees limited value creating pipeline events in the near-term after the company discontinued development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis. He believes it remains too early to assign much value to PRX002 in Parkinson's or PRX004 in ATTR amyloidosis.
06/15/18
CANT
06/15/18
NO CHANGE
Target $18
CANT
Overweight
Prothena price target raised to $18 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner raised his price target for Prothena to $18 citing his analysis of the potential value of the company's drug discovery platform and management's recently announced restructuring plan. The analyst reiterates a Overweight rating on the shares.
LZB La-Z-Boy
$33.25

0.1 (0.30%)

08/01/17
08/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MGM Resorts (MGM) downgraded to Neutral from Buy at UBS with analyst Robin Farley saying the current valuation, with the shares up 37% over the past 12 months, now captures much of the value of the REIT transaction and improving Las Vegas outlook. 2. Boardwalk Pipeline (BWP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Elvira Scotto saying she expects the stock to be "range bound" until its 2019-2020 outlook become clearer. 3. La-Z-Boy (LZB) downgraded to Neutral from Buy at Sidoti with analyst Anthony Lebiedzinski saying shares are approaching his $36 price target. 4. Regeneron (REGN) downgraded to Underperform from Neutral at Baird with analyst Brian Skorney saying Dupixent expectations have gotten ahead of themselves and consensus numbers currently reflect an overlap with Cosentyx sales which looks like an overestimate. 5. Corporate Office Properties (OFC) downgraded to Sell from Hold at Stifel with analyst John Guinee saying he believes that the Real Estate Investment Trust will be hurt by "persistently weak leasing economics," the expirations of a large number of its leases with high rents, and efforts by defense and IT organization to keep rent costs low. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/17
SIDC
08/01/17
DOWNGRADE
SIDC
Neutral
La-Z-Boy downgraded to Neutral from Buy at Sidoti
Sidoti analyst Anthony Lebiedzinski downgraded La-Z-Boy to Neutral due to shares approaching his $36 price target.
ORCL Oracle
$46.29

-0.25 (-0.54%)

06/15/18
KEYB
06/15/18
NO CHANGE
KEYB
Sector Weight
Oracle should report 'in-line' cloud growth for Q4, says KeyBanc
KeyBanc analyst Monika Garg reiterated a Sector Weight rating on Oracle ahead of its June 19 earnings report, telling investors that she believes the company will post "in-line" Q4 cloud growth. While Oracle has "interesting" growth opportunities, she says the company's progress towards cloud is taking longer than expected, and as cloud peers have higher cloud growth from larger bases, additional pressure is placed on Oracle.
06/14/18
NOMU
06/14/18
NO CHANGE
Target $60
NOMU
Buy
Oracle price target lowered to $60 from $64 at Nomura Instinet
Nomura Instinet analyst Christopher Eberle lowered his price target for Oracle to $60 ahead of the company's Q4 results on June 19. The analyst trimmed his estimates to account for currency and expectations for more modest revenue acceleration in fiscal 2019. He remains optimistic, however, on Oracle's transition and model growth reacceleration as the year progresses. Eberle keeps a Buy rating on the shares, which JPMorgan this morning downgraded to Neutral.
06/14/18
06/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oracle (ORCL) downgraded to Neutral from Overweight at JPMorgan with analyst Mark Murphy saying the shares have risen from the $30s into the high $40s over the last two years, but the company's fundamental performance has remained inconsistent. 2. Kohl's (KSS) downgraded to Neutral from Buy at Citi with analyst Paul Lejuez citing valuation. 3. Toll Brothers (TOL) downgraded to Hold from Buy at Zelman. 4. PGT, Inc. (PGTI) downgraded to Hold on valuation at Gabelli with analyst Alvaro Lacayo citing valuation. 5. XPO Logistics (XPO) downgraded to Neutral from Buy at BofA/Merrill with analyst Ariel Rosa citing limited upside following the recent gain in shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/14/18
JPMS
06/14/18
DOWNGRADE
Target $53
JPMS
Neutral
JPMorgan downgrades Oracle after CIO survey shows spending contraction
JPMorgan analyst Mark Murphy downgraded Oracle (ORCL) to Neutral from Overweight and lowered his price target for the shares to $53 from $55. The stock closed yesterday down 18c to $48.27. The shares have risen from the $30s into the high $40s over the last two years, but the company's fundamental performance has remained inconsistent, Murphy tells investors in a research note. Further, the analyst notes that in his firm's recent survey of 154 chief investment officers, Oracle received the largest number of indications for planned spending contraction this year, materially more than the second-worst company. The CIOs indicate contraction in Oracle spending this year, placing the company alongside IBM (IBM), Checkpoint (CHKP), and CA (CA), Murphy contends. He notes the results of his firm's CIO surveys over the years "have been highly predictive."
FDX FedEx
$258.35

-5.295 (-2.01%)

06/19/18
ARGS
06/19/18
NO CHANGE
Target $290
ARGS
Buy
FedEx benefiting from growing e-commerce and strong consumer sector, says Argus
Argus analyst John Eade kept his Buy rating and $290 price target on FedEx ahead of its Q4 earnings later today, saying the stock is a "suitable core holding in a diversified portfolio". Eade notes the company has benefited from solid growth in the consumer sector and growth in e-commerce, which is still below 20% of its overall business. The analyst also expects the management to continue making investments in operations, improving efficiencies and growing margins. Eade also expects FedEx to return to double-digit core growth in FY19.
06/14/18
OPCO
06/14/18
NO CHANGE
Target $288
OPCO
Outperform
FedEx price target raised to $288 from $282 at Oppenheimer
Oppenheimer analyst Scott Schneeberger raised his price target for FedEx to $288 from $282 as he anticipates continued double-digit revenue growth in Q4 on strong business conditions across the company's Express, Ground and Freight segments. The analyst is confident the company achieves overall Q4 margin expansion year over year. He reiterates an Outperform rating on the shares.
06/14/18
COWN
06/14/18
NO CHANGE
Target $280
COWN
Outperform
FedEx should reach inflection for margin contraction during quarter, says Cowen
Cowen analyst Helane Becker noted FedEx will report Q4 earnings after the market closes on June 19 and she believes the quarter will mark an inflection for margin contraction. She expects to see improved margins at Ground and Freight due to solid pricing trends and ongoing volume growth. She also sees no lingering TNT issues at Express while the recent 30% increase in its dividend should be viewed favorably by investors. Becker reiterated her Outperform rating on FedEx shares.
06/15/18
FBCO
06/15/18
NO CHANGE
Target $306
FBCO
Outperform
Buy-side expectations for FedEx 'not elevated,' says Credit Suisse
Credit Suisse analyst Allison Landry maintained an Outperform rating and $306 price target on FedEx, telling investors in a research note that her sentiment survey suggests that many investors expect the company to guide in the $17.15-$17.65 range and that buy-side expectations are not elevated heading into the print. She says that the hurdle to clear for shares to move higher is not "overly difficult," but FedEx will need to issue guidance that "roughly brackets" the consensus, reiterate the Express profit improvement range by 2020 and "keep a lid on CapEx" at about $6B. The key for the stock to work for the foreseeable future is management commentary that can help investors bridge to 2020 earnings and/or free cash flow, she says.
ANIK Anika Therapeutics
$45.99

0.9 (2.00%)

01/24/18
FANA
01/24/18
UPGRADE
Target $68
FANA
Overweight
Anika Therapeutics upgraded to Overweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda upgraded Anika Therapeutics to Overweight and raised his price target for the shares to $68 from $45. A meeting with management gives the analyst confidence that Anika can effectively commercialize products without having to use DePuy Mitek as a marketing partner. In addition to a "deep product pipeline, this osteoarthritis therapy leader has a strong margin profile," Munda tells investors in a research note.
05/04/18
BRRR
05/04/18
UPGRADE
Target $39
BRRR
Outperform
Anika Therapeutics upgraded to Outperform from Market Perform at Barrington
Barrington analyst Michael Petusky upgraded Anika Therapeutics to Outperform with a $39 price target. Though the stock "deserved to be taken to the proverbial woodshed yesterday" following the Q1 results, the 25% selloff "feels somewhat overdone," Petusky tells investors in a research note. The analyst sees longer-term opportunities for growth and margin expansion.
02/23/18
BRRR
02/23/18
DOWNGRADE
BRRR
Market Perform
Anika downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Anika Therapeutics to Market Perform saying the shares are near full value following the company's Q4 results. Anika's operating expenses will ramp meaningfully in 2018, reducing near-term profitability and likely capping the share price over the next few quarters, Petusky tells investors in a research note.
01/26/18
SIDC
01/26/18
INITIATION
SIDC
Buy
Anika Therapeutics initiated with a Buy at Sidoti
KIN Kindred Biosciences
$10.00

-0.55 (-5.21%)

12/27/17
KING
12/27/17
INITIATION
KING
Neutral
Kindred Biosciences initiated with a Neutral at CL King
CL King started Kindred Biosciences with a Neutral rating.
12/27/17
12/27/17
NO CHANGE

On The Fly: Top analyst actions
Catch up on today's top analyst actions with this list compiled by The Fly: 1. Hancock Holding (HBHC) upgraded to Outperform from Market Perform at Hovde Group. 2. Callaway Golf (ELY) downgraded to Sell from Neutral at Compass Point with analyst Casey Alexander cutting his price target for the shares to $13.50 from $14.50. 3. Celgene (CELG) downgraded to Market Perform from Outperform at Bernstein. 4. Edison International (EIX) downgraded to Hold from Buy at Edward Jones. 5. Aratana Therapeutics (PETX) and Kindred Biosciences (KIN) were initiated with a Neutral at CL King. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/18
HCWC
05/09/18
NO CHANGE
Target $12
HCWC
Buy
Kindred Biosciences price target raised to $12 from $10.50 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Kindred Biosciences to $12 saying approval of Mirataz validates the company's business model. This is the first approved drug coming from the Kindred's therapeutic pipeline, Ramakanth tells investors in a research note. The approval not only provides Kindred with a "substantial" revenue stream, but also signals the success of its business model of repurposing human drug for the veterinarian use, the analyst contends. He keeps a Buy rating on Kindred Biosciences.
05/23/18
EROP
05/23/18
INITIATION
Target $16.75
EROP
Buy
Kindred Biosciences initiated with a Buy at Euro Pacific
Euro Pacific initiated Kindred Biosciences with a Buy and $16.75 price target.
SBUX Starbucks
$57.43

0.22 (0.38%)

06/05/18
BARD
06/05/18
NO CHANGE
Target $65
BARD
Outperform
Starbucks loss of Schultz raises risk profile, says Baird
Baird analyst David Tarantino believes the departure of Howard Schultz from Starbucks raises the risk profile for investors. The analyst said he is disappointed to see such an iconic leader exit the business, but he is cautiously optimistic the current leadership team can execute the current strategies effectively. Tarantino lowered his price target to $65 from $68 on Starbucks shares, but maintains an Outperform rating.
05/21/18
UBSW
05/21/18
NO CHANGE
Target $66
UBSW
Buy
Starbucks deserves a premium multiple, says UBS
UBS analyst Dennis Geiger said Starbucks has broad-based quality growth and as a results deserves its premium multiple. The analyst went to China and saw a strong and increasingly important growth opportunity. The analyst said new products, digital, and market tailwinds will help contribute to its positive same-store-sales growth. Geiger reiterated his Buy rating and $66 price target on Starbucks shares.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $72
MSCO
Overweight
Schultz leaving a loss, but Morgan Stanley says change can benefit Starbucks too
Morgan Stanley John Glass said Howard Schultz stepping down from his role of executive chairman must be considered a loss for Starbucks, but he added that change can have some potential benefits as well. Glass contends Starbucks is at an important crossroads in its strategy and he believes this event perhaps could further accelerate this process as the new leadership team put the company on a path toward the future with their own ideas. Glass maintains his Overweight rating and $72 price target on Starbucks shares.
06/19/18
SPHN
06/19/18
NO CHANGE
Target $58
SPHN
Equal Weight
Starbucks has no 'meaningful initiatives to improve sales', says Stephens
Stephens analyst Will Slabaugh kept his Equal Weight rating and $58 price target on Starbucks after its Q3 update, saying the 1% comps growth forecast implies a slowdown from the 3% start that was mentioned in the company's Q2 conference call. The analyst notes that he remains concerned about the lack of "meaningful initiatives to improve sales trajectory" at Starbucks, which would support its valuation expansion.
GE General Electric
$12.96

-0.24 (-1.82%)

05/30/18
JPMS
05/30/18
NO CHANGE
Target $11
JPMS
Underweight
GE Capital remains 'underappreciated risk,' says JPMorgan
JPMorgan analyst Stephen Tusa believes GE Capital "remains an underappreciated risk." In a new research note titled "GECS: Not Gone and Not to Be Forgotten; Part 3, Recent Disclosure Suggests Further Action Needed to 'De-Risk," Tusa says the math suggests more capital may be needed, even without another charge from lingering liabilities. The analyst sees either $22B in incremental asset wind down versus the standing plan, or a $3B capital contribution. While many investors are discounting January's Insurance charge as one of the last "shoes to drop," it is "more of a wake-up call around a GECS book that continues to operate with the burden of a systemic approach to making short-term earnings look better with ultimately uneconomic long-term moves," Tusa writes. He has an Underweight rating on General Electric with an $11 price target.
05/29/18
COWN
05/29/18
NO CHANGE
Target $125
COWN
Outperform
Wabtec price target raised to $125 from $99 at Cowen
Cowen analyst Matt Elkott raised his price target on Wabtec (WAB) to $125 from $99 citing its merger with GE Transportation (GE). He believes Wabtec is the most comprehensive and unique play on global rail markets and there is no direct publicly traded comp. Elkott reiterated his Outperform rating on Wabtec shares.
06/01/18
UBSW
06/01/18
NO CHANGE
Target $16
UBSW
Neutral
General Electric can cover dividend into 2019, says UBS
UBS analyst Steven Winoker noted investors are concerned about General Electric's ability to pay its dividend. The analyst believes the company can generate enough cash and maintain a strong credit rating if they can execute asset sales. He believes the company can cover the dividend in 2018 and 2019 and most likely into 2020, but argues a bigger free cash flow cushion is warranted. Winoker maintained his Neutral rating and $16 price target on General Electric shares.
06/04/18
JPMS
06/04/18
NO CHANGE
Target $11
JPMS
Underweight
General Electric needs $30B in cash, JPMorgan's Tusa says
JPMorgan analyst Stephen Tusa says he's watching for General Electric's new board and management to set the longer-term path for a "new GE" as the company's CEO transition approaches its one-year anniversary. In a research note titled "Will The Page Officially Turn In June?," Tusa argues that investors "deserve clarity on the path forward" following "mixed messages" and the debate around portfolio value. The analyst continues to see the need for GE to "de-risk substantially," which he believes includes the need for cash and a cut to the dividend. This is not only about survival, but positioning the company to, as CEO Flannery put it recently, "flourish," Tusa writes. The analyst's preliminary math shows the need for $30B in cash to get to 2.5 times leverage as per ratings agencies. Tusa keeps an Underweight rating on General Electric with an $11 price target.
VALE Vale
$12.97

-0.21 (-1.59%)

04/24/18
RBCM
04/24/18
DOWNGRADE
RBCM
Sector Perform
Vale downgraded to Sector Perform from Outperform at RBC Capital
04/24/18
RBCM
04/24/18
DOWNGRADE
Target $16
RBCM
Sector Perform
Vale downgraded to Sector Perform at RBC Capital on iron ore market pressure
As reported earlier, RBC Capital analyst Tyler Broda downgraded Vale to Sector Perform from Outperform with a price target of $16. Broda says that although the company is in a "robust and improving structural position", he expects iron ore markets to come under further pressure in the coming months on slower growth in demand from China, just as Vale production in Q1 reached record levels. The analyst also points to the Samarco settlement being pushed back by 66 days, which should not impact shares in the short term but also "pushes back any positive catalyst from a restart."
03/27/18
MACQ
03/27/18
DOWNGRADE
MACQ
Neutral
Vale downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Grant Sporre downgraded Vale to Neutral from Outperform, citing a general preference for Metals over Bulk commodities and his view that it is unlikely to benefit from high grade premiums as steel margins ease lower.
01/16/18
DBAB
01/16/18
DOWNGRADE
DBAB
Hold
Vale downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Vale to Hold while raising his price target for the shares to $12.50 from $12. The analyst cites valuation for the downgrade as he believes the company's catalysts have largely played out.

TODAY'S FREE FLY STORIES

DERM

Dermira

$10.57

-0.16 (-1.49%)

17:00
07/17/18
07/17
17:00
07/17/18
17:00
Hot Stocks
Breaking Hot Stocks news story on Dermira »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

16:59
07/17/18
07/17
16:59
07/17/18
16:59
Earnings
Texas Instruments reports Q2 EPS $1.40, consensus $1.31 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

DERM

Dermira

$10.57

-0.16 (-1.49%)

16:57
07/17/18
07/17
16:57
07/17/18
16:57
Hot Stocks
Breaking Hot Stocks news story on Dermira »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$72.66

0.38 (0.53%)

16:53
07/17/18
07/17
16:53
07/17/18
16:53
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NLY

Annaly Capital

$10.42

0.04 (0.39%)

, MTGE

MTGE Investment

$19.70

0.05 (0.25%)

16:46
07/17/18
07/17
16:46
07/17/18
16:46
Hot Stocks
Annaly Capital extends exchange offer to acquire MTGE Investment »

Annaly Capital Management…

NLY

Annaly Capital

$10.42

0.04 (0.39%)

MTGE

MTGE Investment

$19.70

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

16:42
07/17/18
07/17
16:42
07/17/18
16:42
Hot Stocks
Texas Instruments CEO Brian Crutcher resigns, Rich Templeton to succeed »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CSX

CSX

$64.42

0.46 (0.72%)

16:41
07/17/18
07/17
16:41
07/17/18
16:41
Hot Stocks
Breaking Hot Stocks news story on CSX »

CSX advances 3.2% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WTFC

Wintrust Financial

$88.40

0.25 (0.28%)

16:40
07/17/18
07/17
16:40
07/17/18
16:40
Earnings
Wintrust Financial reports Q2 EPS $1.53, consensus $1.44 »

Edward J. Wehmer,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

UBNK

United Financial

$17.40

-0.07 (-0.40%)

16:39
07/17/18
07/17
16:39
07/17/18
16:39
Earnings
United Financial reports Q2 EPS 31c, consensus 30c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

16:38
07/17/18
07/17
16:38
07/17/18
16:38
General news
API crude inventories for week of July 13 »

API reports that crude…

CASI

Casi Pharmaceuticals

$7.26

-0.215 (-2.88%)

16:38
07/17/18
07/17
16:38
07/17/18
16:38
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHAK

Shake Shack

$66.86

1 (1.52%)

16:37
07/17/18
07/17
16:37
07/17/18
16:37
Hot Stocks
Shake Shack plans to expand to Manila in spring 2019 »

Shake Shack said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 07

    Aug

  • 08

    Aug

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

16:36
07/17/18
07/17
16:36
07/17/18
16:36
Hot Stocks
Breaking Hot Stocks news story on Sonic Automotive »

Sonic Automotive down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

16:34
07/17/18
07/17
16:34
07/17/18
16:34
Earnings
Sonic Automotive sees Q2 adjusted cont ops EPS 32c-36c, consensus 49c »

Sonic Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOPE

Hope Bancorp

$17.52

-0.05 (-0.28%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Hope Bancorp raises quarterly dividend to 14c per share from 13c »

Hope Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 07

    Nov

NTRS

Northern Trust

$105.64

0.18 (0.17%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Northern Trust approves new stock repurchase program of 25M shares »

Northern Trust announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CSX

CSX

$64.42

0.46 (0.72%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Earnings
Breaking Earnings news story on CSX »

CSX expects mid-single…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

NTRS

Northern Trust

$105.64

0.18 (0.17%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Northern Trust raises dividend 30% to 55c »

Northern Trust, holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

HOPE

Hope Bancorp

$17.52

-0.05 (-0.28%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Earnings
Hope Bancorp reports Q2 EPS 36c, consensus 37c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 07

    Nov

FULT

Fulton Financial

$16.70

-0.05 (-0.30%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Earnings
Fulton Financial reports Q2 EPS 20c, consensus 14c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 14

    Aug

CSX

CSX

$64.42

0.46 (0.72%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Hot Stocks
CSX reports Q2 operating ratio 58.6% versus 67.4% in same quarter last year »

Capital investments in Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

16:30
07/17/18
07/17
16:30
07/17/18
16:30
Options
Preliminary option volume of 17.8M today »

Preliminary option volume…

16:30
07/17/18
07/17
16:30
07/17/18
16:30
General news
U.S. TIC report showed foreign accounts bought $69.9 B in net U.S. assets in May »

U.S. TIC report showed…

CARA

Cara Therapeutics

$21.60

0.435 (2.06%)

16:29
07/17/18
07/17
16:29
07/17/18
16:29
Syndicate
Cara Therapeutics announces offering of 4.5M shares of common stock »

Cara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$72.66

0.38 (0.53%)

16:29
07/17/18
07/17
16:29
07/17/18
16:29
Hot Stocks
United Continental sees FY18 total regional aircraft 554 at year end »

Up 36 units from FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.